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Mycobacterium Tuberculosis-Induced Cell Death of
Primary Human Monocytes and Macrophages Is Not
Significantly Modulated by Tumor Necrosis Factor-
Targeted Biologicals
Norbert Reiling1,2, Dagmar Schneider1,2 and Stefan Ehlers1
Differential induction of cell death in mycobacteria-infected monocytes and macrophages has been invoked as
one possible mechanism by which some tumor necrosis factor (TNF)-targeted biologicals reactivate
tuberculosis more frequently than others. We infected primary human monocytes and monocyte-derived
macrophages with the virulent Mycobacterium tuberculosis strain H37Rv and followed the rate of cell death in
the absence or presence of a wide concentration range of four different TNF-targeted biologicals: infliximab
and adalimumab (both monoclonal antibodies to human TNF) and etanercept and polyethylene-glycols TNFR1
(fusion constructs of human TNFR2 and TNFR1, respectively). None of the TNF-targeted biologicals used
modulated the death rate of monocytes/macrophages induced by infection with M. tuberculosis alone. Our
data support the view that mycobacteria-induced cell death is largely independent of TNF and that the primary
target for differential modulation by TNF-targeted biologicals during tuberculosis is not a recently recruited
monocyte or freshly differentiated macrophage.
Journal of Investigative Dermatology Symposium Proceedings (2007) 12, 26–33. doi:10.1038/sj.jidsymp.5650033
INTRODUCTION
The increased clinical use of tumor necrosis factor (TNF)
antagonists has been accompanied by increased reporting of
granulomatous infectious diseases, including tuberculosis
(TB), histoplasmosis, and other less common conditions
(Weisman 2002; Fleischmann 2003). Clinical reports of
granulomatous infections indicate a greater incidence of
reactivation TB with infliximab and adalimumab, both anti-
TNF antibodies, than by etanercept, a soluble TNFR2 fusion
construct (Fleischmann et al., 2002; Gardam et al., 2003;
Wallis et al., 2004; Keystone, 2005). This is consistent with
the apparent differential therapeutic activities of these two
classes of drugs for granulomatous inflammatory conditions,
such as Crohn’s disease (Sandborn et al., 2001; Lamprecht
et al., 2002; Sandborn and Hanauer, 2002; Serio, 2003; Utz
et al., 2003). Despite the capacity of both classes of drugs to
neutralize TNF function, the drugs’ respective modes of
action in vivo may therefore differ considerably from each
other. Three hypotheses were discussed that might explain
the more frequent reactivation of latent Mycobacterium
tuberculosis infection by TNF-targeted mAbs than by the
soluble TNF receptor fusion construct: (i) differential net
blockade of TNF bioactivity; (ii) differential inhibition of TNF
signaling; or (iii) differential induction of target cell death,
that is, differential disruption of macrophage and, con-
sequently, granuloma integrity (Ehlers, 2005).
With regards to the third hypothesis, TNF-neutralizing
antibodies have been shown to induce apoptosis both in vitro
and in vivo, whereas no such results have been reported with
etanercept. Specifically, infliximab caused apoptosis in
monocytes from patients with Crohn’s disease through a
caspase 3-dependent pathway, and ex vivo studies in patients
treated with infliximab showed a significant increase in
apoptotic CD3þ lymphocytes in the lamina propria of
colonic biopsies (Lugering et al., 2001; Van den Brande et al.,
2003). Analyses of tissue biopsies in M. tuberculosis-infected
mice following antibody-mediated inhibition of TNF activity
also indicated increased apoptotic activity within granu-
lomatous lesions (Mohan et al., 2001), whereas in patients
treated with infliximab, apoptosis within pulmonary granu-
lomas was apparently decreased (Keane et al., 2001), leaving
this issue unresolved. Thus far, there has been no experi-
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mental study directly documenting the consequence of TNF-
targeted biologicals on M. tuberculosis-infected monocytes
and macrophages with respect to differential induction of
apoptosis.
It is also possible that infliximab – having bound to
membrane-associated TNF on monocytes or lymphocytes –
activates complement or causes antibody-dependent cellular
cytotoxicity via its Fc tail (Scallon et al., 1995). This would
help explain the relatively heightened (albeit still rare)
occurrence of disseminated TB in infliximab-treated patients,
because the lysed granuloma macrophages would spill
M. tuberculosis organism into the bloodstream. However,
extrapulmonary M. tuberculosis has also been documented in
patients treated with etanercept (Gardam et al., 2003; Mohan
et al., 2004). To date, no studies have addressed directly the
issue of whether the different TNF-targeted biologicals
differentially induce the lysis of M. tuberculosis-infected
macrophages.
In this study, it was our goal to determine whether
treatment with TNF-targeted biologicals (infliximab, adali-
mumab, etanercept, and a novel experimental soluble TNFR1
construct with a polyethylene-glycol (PEG) modification)
modulate the death of M. tuberculosis-infected primary
human monocytes and macrophages. Our data indicate that
mycobacteria-induced target cell death proceeds, to a large
extent, independently of TNF.
RESULTS
Mycobacteria induce cell death in human primary monocytes
Mycobacteria have been shown to induce cell death in a
variety of cellular systems. The underlying mechanisms
include induction of apoptosis as well as necrosis (Keane
et al., 1997; Park et al., 2006). In initial infection experiments
using human primary monocytes as well as macrophages, we
observed activation of caspase 3 as well as the release of
lactate dehydrogenase indicating that, indeed, both apoptotic
and necrotic pathways are involved. To monitor comprehen-
sively the influence of TNF-targeted biologicals on M. avium-
and M. tuberculosis-induced overall cell death, we estab-
lished a FACS-based quantitative method using the DNA dye
TO-PRO-3 as indicator of cell death (Van Hooijdonk et al.,
1994). This assay gives a very reliable read-out of overall
death events (both, apoptotic and necrotic) in the culture
system: cells binding TO-PRO-3 are scored as dead, whereas
cells negative for TO-PRO-3 staining are viable. Figure 1
demonstrates that the majority of highly purified human
monocytes remain TO-PRO-3 negative 24 hours after infec-
tion with M. tuberculosis. This changes dramatically after
48 hours, at which time point cells significantly decrease in
size. At 72 hours after placement in culture, almost all cells
are TO-PRO-3 positive, indicating cell death.
We then performed infection experiments using an
increasing multiplicity of infection (MOI) of 1:1, 3:1, and
10:1 M. tuberculosis and monitored cell death at different
time points after infection (24–72 hours). Figure 2 shows that
the induction of monocyte death induced by M. tuberculosis,
as measured by TO-PRO-3, is time and dose dependent.
Similar results were obtained when human monocyte-derived
macrophages were used. For subsequent experiments shown,
a MOI of 1:1 (M. tuberculosis) was used and flow cytometric
analysis was performed at 48 hours after infection.
Supernatants collected from mycobacteria-infected mono-
cytes were added to L929 murine fibroblasts to measure their
cytotoxic potential. In repeated experiments, these super-
natants induced cell death in approximately 90% of the
fibroblasts (data not shown), whereas the addition of
mycobacteria alone did not have this effect. Analysis of
TNF contents in these supernatants by ELISA (R&D Systems,
Wiesbaden, Germany) showed the presence of 0.2–5 ng/ml
depending on the dose used and the time point at which the
cells were analyzed (data not shown). This indicated that cell
death in monocytes induced by M. tuberculosis infection
might be a consequence of TNF.
All TNF-targeted biologicals used efficiently block the cytotoxic
effect of TNF
Based on these observations, we added 5 ng/ml human TNF
on L929 cells in the absence or presence of increasing
concentrations of four different TNF-targeted biologicals
(etanercept, PEGsTNFR1, adalimumab, and infliximab).
Figure 3 shows that all four reagents used blocked the TNF-
mediated cytotoxicity efficiently. Concentrations around
1 mg/ml prevented the TNF-induced cell death almost
completely.
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Figure 1. Flow cytometric analysis of M. tuberculosis-induced cell death.
Human monocytes (2 105) were incubated with M. tuberculosis (MOI 1:1)
for (a) 24 hours, (b) 48 hours, and (c) 72 hours. At the indicated time points the
cells were stained with TO-PRO-3 and analyzed in a flow cytometer. In all
three graphs, forward scatter is depicted versus TO-PRO-3 fluorescence
intensity. (a) At 24 hours, the majority of the cells are located in the lower right
quadrant, representing TO-PRO-3 negative (viable) cells (R2). (b) At 48 hours
after infection, many cells have decreased in size and move to the lower, left
quadrant, still representing TO-PRO-3 negative cells. (c) At 72 hours almost
all cells were located in the upper left quadrant, representing TO-PRO-3
positive (dead) cells (R1).
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M. tuberculosis-induced cell death of human monocytes and
macrophages is not modulated by the addition of TNF-targeted
biologicals in vitro
Monocytes were infected with M. tuberculosis (MOI 1:1) in
the absence or presence of increasing concentrations of TNF-
targeted biologicals ranging from 0.001 to 100 mg/ml and cell
death was analyzed. The selected concentrations in our
experiments covered the range in which these drugs are
used during therapy (Etanercept data sheet. Accessible via:
http://www.medsafe.govt.nz/profs/Datasheet/e/Enbrelinj.htm
(accessed March 2006); Adalimumab data sheet. Accessible
via: http://www.medsafe.govt.nz/profs/Datasheet/h/Humir-
ainj.htm (accessed March 2006); Infliximab data sheet.
Accessible via: http://www.medsafe.govt.nz/profs/Datasheet/
r/Remicadeinj.htm#top (accessed March 2006)). Figure 4
demonstrates that the presence of these very efficient
blockers of TNF-mediated cytotoxicity (Figure 3) did not
influence the rate of cell death significantly, which remained
in the range of 60% for monocytes (40% for macrophages,
Figure 5) regardless of the dose of biological used. Some
reduction in cell death was noted in monocyte cultures
treated with PEGsTNFR1, but this was a somewhat incon-
sistent finding and was not dose dependent (Figure 4c).
Macrophage death was increased slightly in the presence of
high doses of etanercept, though this effect did not reach
statistical significance (Figure 5). Macrophage cell death was
also increased slightly in the presence of adalimumab, but
this effect was not dose dependent and also did not reach
statistical significance (Figure 5).
In order to exclude potential adverse effects of the
substances on the viability of human primary monocytes
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Figure 2. The induction of cell death by M. tuberculosis in human
monocytes is time and dose dependent. Monocytes (2 105) were incubated
in the absence or presence of M. tuberculosis and cell death was analyzed as
described in Materials and Methods. (a) Incubation at different multiplicities
of infection (1:1, 3:1, and 10:1) for 48 hours. Staurosporine (Stau) (300 nM)
was used as a positive control. (b) Analysis at different time points (24 hours,
48 hours and 72 hours) at a MOI of 1:1. Means7SD of three independent
experiments for each set of experiments (a and b) is shown. Med, medium.
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Figure 3. TNF-targeted biologicals block TNF-induced cell death in fibroblast cultures. L929 fibroblasts at a density of 2.5105 per well were incubated with
5 ng/ml TNF in the absence or presence of increasing concentrations of the TNF antagonists etanercept, PEGsTNFR1, adalimumab and infliximab for 20 hours.
After crystal violet staining of the remaining cells, absorption was measured in a microplate reader at 550 nm. (a–d) Means7SD of two sets of independent
experiments are shown. Med, medium.
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Figure 4. M. tuberculosis-induced cell death of human monocytes is not modulated by the addition of TNF antagonists in vitro. Human monocytes (2 105)
were incubated for 48 hours with M. tuberculosis (MOI 1:1) in the absence or presence of increasing concentrations of the TNF antagonists (a) etanercept,
(b) adalimumab, (c) PEGsTNFR1, and (d) infliximab. Cells were subsequently stained with TO-PRO-3 and analyzed in a flow cytometer. Means7SD of five
independent experiments performed with cells from independent individuals are shown. Statistical analysis was performed using the Wilcoxon test. No
significant differences between untreated and TNF antagonist treated cells were observed. Med, medium.
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Figure 5. M. tuberculosis-induced cell death of human macrophages is not modulated by the addition of TNF antagonists in vitro. Human macrophages
(2105) were incubated for 48 hours with M. tuberculosis (MOI 1:1) in the absence or presence of increasing concentrations of the TNF antagonists
(a) etanercept, (b) adalimumab, (c) PEGsTNFR1, and (d) infliximab. Cells were subsequently stained with TO-PRO-3 and analyzed in a flow cytometer.
Means7SD of five independent experiments performed with cells from independent individuals are shown. Statistical analysis was performed using the
Wilcoxon test. No significant differences between untreated and TNF antagonist-treated cells were observed. Med, medium.
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under the used conditions, we cultured the cells in the
absence or presence of increasing concentrations of the four
drugs and measured the amount of TO-PRO-3-positive cells
after 48 hours. None of the TNF antagonists used had a
significant, detrimental effect on cellular viability, even when
used at concentrations of 100mg/ml. Similar results were
obtained with human monocyte-derived macrophages (data
not shown).
The effect of human serum in this culture system was also
analyzed. In the presence of 2–10% active, non-heat-
inactivated, pooled AB serum, neither infliximab, adalimu-
mab, etanercept nor PEGsTNFR1 modulated the rate of lysis
significantly (as determined by lactate dehydrogenase
release; Takara lactate dehydrogenase Cytotoxicity Detection
Kit, Mobitec, Go¨ttingen Germany) in human monocytes or
macrophages infected with M. tuberculosis, regardless of the
dose of biological used (data not shown).
Primary human monocytes and macrophages are highly
resistant to TNF-induced cell death in vitro
The fact that TNF-neutralizing reagents had no effect on
mycobacteria-induced cell death suggested that monocytes
and macrophages might be largely refractory to TNF-
mediated cytotoxicity. Indeed, when exposed to a wide
concentration range of recombinant TNF, which covers the
range of endogenously produced TNF release in culture (in
the lower ng/ml range), myeloid cells – in stark contrast to
fibroblasts –were resistant with regard to the induction of cell
death (Figure 6). In repeated experiments, a slightly protective
role of TNF was even observed, in that TNF treatment
resulted in extended survival of monocytes. Only at TNF
concentrations approximately 200- to 1,000-fold higher than
endogenously produced TNF levels was a measurable
increase in monocyte cell death observed. The same type
of experiment was performed with human monocyte-derived
macrophages giving identical results (data not shown).
DISCUSSION
We studied the role of TNF in mycobacteria-induced cell
death in primary human monocytes and macrophages. None
of the TNF-targeted biologicals tested (etanercept,
PEGsTNFR1, adalimumab, and infliximab) modulated the
rate of cell death induced by a virulent strain of
M. tuberculosis (H37Rv). We interpret these findings as a
strong indication that the cell death, which is induced in
monocytes and macrophages following mycobacterial infec-
tion is TNF-independent predominantly. As a consequence, it
appears unlikely that the different rates of reactivation TB in
patients treated with different TNF-targeted biologicals can be
attributed to a differential induction of monocyte or macro-
phage cell death by any of the biologicals investigated here.
TNF is a critical mediator in the activation of immune cells
with regard to the antibacterial, the antiviral, as well as the
antitumor response of the immune system. Depending on the
cell type, TNF concentration may have protective as well as
cytotoxic functions and is able to induce apoptotic as well as
necrotic cell death (reviewed by Locksley et al., 2001;
Wajant et al., 2003). Whereas a variety of tumor cell lines
and fibroblasts undergo apoptosis in response to TNF
(Granger et al., 1969; Carswell et al., 1975; Fransen et al.,
1986), TNF has been shown to protect human primary
monocytes from undergoing programmed cell death (Mangan
et al., 1991). Low concentrations of TNF have even been
shown to enhance survival of human as well as murine
primary monocytes and macrophages (Du¨rrbaum-Landmann
et al., 1996; Shi et al., 2003). The results obtained in our
study corroborate these findings. Human monocytes and
macrophages were found to be 200- to 1,000-fold less
sensitive to TNF-induced cytotoxicity than fibroblasts. The
decision whether a cell is sensitive or refractory to TNF-
induced cell death is likely to depend on a distinct TNF
receptor 1 and -2 expression pattern on the cell surface as
well as cell type-specific signaling events induced by these
receptors (reviewed by Wajant et al., 2003). This may in part
explain the discrepant results obtained with mycobacteria-
infected alveolar macrophages (Keane et al., 1997; Bal-
cewicz-Sablinska et al., 1998; Fratazzi et al., 1999; Spira
et al., 2003). In these studies, human alveolar macrophages
infected with M. tuberculosis were found to undergo
programmed cell death, a virulent strain (H37Rv) inducing
significantly less apoptosis than an avirulent strain (H37Ra).
Along similar lines, Park et al. (2006) who compared a
M. tuberculosis laboratory strain with several clinical isolates
in a murine in vivo model, also showed that the clinical
isolates led to an enhanced rate of cell death, which was
reported to be owing mainly to necrotic processes. This
inverse correlation of mycobacterial virulence and induction
of cell death was attributed in part to the superior capacity of
the virulent strain to induce the release of soluble TNFR2 into
the supernatant, antagonizing the effect of TNF, at least in the
in vitro system using alveolar macrophages (Balcewicz-
Sablinska et al., 1998). In addition, the virulent strain of M.
tuberculosis was found to modulate the TNF-induced
proapoptotic gene expression pattern in alveolar macro-
phages (Spira et al., 2003).
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Figure 6. Primary human monocytes are highly resistant to TNF-induced cell
death in vitro. Human monocytes (2105) were incubated for 48 hours in the
absence or presence of increasing concentrations of TNF as indicated. Cells
were subsequently stained with TO-PRO-3 and analyzed in a flow cytometer.
Means7SD of three independent experiments performed with cells from
three independent individuals are shown. Med, medium.
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It is possible that cell death induced by virulent strains of
M. tuberculosis is largely independent of TNF (as shown in
our study), but that the high rates of cell death induced by less
virulent mycobacterial strains may be predominantly TNF
mediated. This would be consistent with the finding that less
virulent mycobacterial strains induce significantly higher
amounts of TNF than virulent strains (Reed et al., 2004;
Blumenthal et al., 2005).
In order to explain the reactivation of TB during treatment
of patients with TNF antagonists, two mechanisms of target
cell death have been discussed. One is based on the
observation by Scallon et al. (1995), that a cell expressing
mTNF, for example, macrophages and T cells, may be lysed
by the complement system after binding of anti-TNF anti-
body, as shown by the lysis of a constitutively mTNF
expressing, transfected T-cell line after addition of the anti-
TNF antibody cA2. In this study, however, we used highly
purified human monocytes and macrophages and did not
observe an enhanced complement-dependent lysis of the
cells by all four TNF antagonists used. Also, the use of human
serum instead of fetal calf serum had no effect on the rate of
TO-PRO-3-positive, dead cells in our experiments.
The second hypothesis focused on cell death induced by
reverse signaling in mTNF expressing immune cells after the
binding of TNF antagonists, which in consequence would
also lead to reduced TNF levels (Van den Brande et al., 2002,
2003). Watts et al. (1999) postulated this mechanism based
on experiments obtained with a LPS-stimulated murine
macrophage cell line (RAW264.7): binding of sTNF1 on
mTNF in these cells led to a rise in intracellular calcium
levels, which has been interpreted as TNF antagonist-induced
signaling in mTNF-bearing cells. This effect has also been
reported by Higuchi et al. (1997), who showed that binding
of anti-TNF antibodies to mTNF expressing virus infected
T cells changed their capacity to stimulate IgM production of
B cells, by inducing an enhanced calcium release as well as
an enhanced IL-2 and IFN-g release.
As the generation of TNF includes the formation of mTNF
before the cleavage by tumor necrosis factor-a-converting
enzyme (Tang et al., 1996; Black et al., 1997), it is highly
likely that mTNF was present on the cell surface of
monocytes and macrophages after mycobacterial stimulation
in our assay system. As we did not observe an influence of the
TNF antagonists on cell death in the absence or presence of
mycobacteria, we conclude that primary human monocytes
and macrophages may behave differently with regard to both
complement-induced lysis or reverse signaling after binding
of an anti-TNF antibody compared to transfected cell lines.
However, further work is needed to quantitate the presence
and define the role of mTNF expression in human primary
myeloid cells.
In its strategy to fight successfully and eradicate a
mycobacterial infection and to limit the dissemination of
the pathogen, the immune system activates distinct cell
populations (e.g. alveolar macrophages, CD4þ -, CD8þ -,
gd-T cells, TH1 effector cells as well as natural killer cells) to
produce critical mediators such as TNF, IL-12, and IFN-g. The
interplay of these cellular as well as the soluble factors are
important to initiate and control the migration of immune
cells to the site of infection (reviewed by Algood et al., 2005;
Ulrichs and Kaufmann, 2006). An essential player in the
control of mycobacterial infections is TNF, as it is a key
regulator of granuloma formation and maintenance at the
infectious foci (reviewed by Ehlers, 2003; Algood et al.,
2005). Granulomas are highly dynamic and flexible multi-
cellular compartments, whose integrity depends on finely
balanced, tuned local cytokine and chemokine production
(reviewed by Adams, 1976; Flynn and Chan, 2001; Ehlers
and Ho¨lscher, 2006) to enable an effective antimycobacterial
response, which does not lead to a severe damage of the
surrounding healthy tissue. Following mycobacterial infec-
tions, TNF- and TNFR1 (p55) gene-deficient mice develop
severe tissue damage, which is due to the lack of the
regulation of the T-cell response by activation-induced TNF-
mediated cell death of these lymphocytes (Ehlers et al.,
2000).
Our in vitro study largely excludes the invading monocyte
and recently differentiated macrophage as a prime target
whose integrity may be modulated by TNF-targeted biologi-
cals in the course of M. tuberculosis infection. It is still
possible that resident tissue macrophages, or cells with a
different distribution of TNF receptors, may be affected by
these reagents, particularly following activation by myco-
bacterial infection. However, it appears more likely that other
cells important in the regulation of the inflammatory response
to M. tuberculosis, in particular T cells, may be more
sensitive to local TNF levels and their neutralization and may
even be differentially affected by different TNF-targeted
biologicals, depending on the density of TNF receptors on
their surface. Indeed, increased apoptosis of T cells following
treatment of patients with monoclonal anti-TNF antibodies
(infliximab and adalimumab), but not soluble receptor
constructs (etanercept) was reported (Vigna-Perez et al.,
2005; Sieper and Van Den, 2005). If the loss or dysregulation
of M. tuberculosis-specific T cells could be substantiated
further in this process, this would readily explain the
occurrence of reactivation TB.
MATERIALS AND METHODS
TNF antagonists
Etanercept (Enbrels) and PEGsTNFR1 (a soluble human TNFR1
construct with a PEG tail to increase its serum half-life) were
provided by Amgen Inc (Thousand Oaks, CA). Adalimumab
(Humiras) was purchased from Abbott, Wiesbaden, Germany, and
infliximab (Remicades) was obtained from Essex Pharma, Munich,
Germany.
Bacteria
M. tuberculosis strain H37Rv was obtained from the Trudeau
Institute (Saranac Lake, NY) and cultured in Middlebrook 7H9
medium supplemented with OADC (oleic acid, albumin dextrose,
catalase; BD Biosciences, Heidelberg, Germany) to mid-logarithmic
phase. Aliquots were frozen at 701C until needed. For stimulation
experiments, strains were thawed at room temperature and spun
down with 1000 g for 10 minutes to adjust for inoculum size.
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Bacteria were resuspended in phosphate-buffered saline and added
to the cells for the times indicated.
Cell preparation and differentiation
Human primary monocytes and monocyte-derived macrophages
were isolated and cultured as described previously (Reiling et al.,
2001). Experiments with human primary cells were approved by the
regional Ethics Review Board. Cell viability before experiments was
measured by trypan blue exclusion and was always greater than 95%.
Analysis of cell death by flow cytometry
Cells were stained with TO-PRO-3 Iodide (2 mM; Mobitec, Go¨ttingen,
Germany), which has been used in previous studies to determine
apoptotic and necrotic cell death (Van Hooijdonk et al., 1994;
Suzuki et al., 1997; Diaz-Romero et al., 2002). Staurosporine
(300 nM, Calbiochem, Darmstadt, Germany) was used as positive
control (Bertrand et al., 1994). Subsequently the cells were analyzed
in a flow cytometer (FACS Calibur, BD Biosciences, Heidelberg,
Germany) using the HeNe laser.
L929 cytotoxicity assay
TNF cytotoxicity was analyzed in a 20-hour cytotoxicity assay using
L929 cells in the presence of 1.25 mg/ml actinomycin D. Cells were
stained subsequently with crystal violet and absorbance was
measured at 550 nm (Matthews and Neale, 1987).
Statistical analysis
Data obtained from independent experiments are presented as
means7SD, and were compared by the Wilcoxon test. Differences
were considered significant for P-values o0.05.
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